SRBCF (Sirona Biochem) Equity-to-Asset: -4.28 (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sirona Biochem Equity-to-Asset?

Sirona Biochem SRBCF -99.98% Equity-to-Asset is -4.28 as of Jul. 2024.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sirona Biochem's Total Stockholders Equity for the quarter that ended in Jul. 2024 was $-2.51 Mil. Sirona Biochem's Total Assets for the quarter that ended in Jul. 2024 was $0.59 Mil. Therefore, Sirona Biochem's Equity to Asset Ratio for the quarter that ended in Jul. 2024 was -4.28.

The historical rank and industry rank for Sirona Biochem's Equity-to-Asset or its related term are showing as below:

SRBCF's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.69
* Ranked among companies with meaningful Equity-to-Asset only.

Sirona Biochem  (OTCPK:SRBCF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sirona Biochem Equity-to-Asset Related Terms

Sirona Biochem Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Sirona Biochem's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem Equity-to-Asset Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.02 -0.07 0.17 -2.43

Sirona Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -2.43 -3.98 -4.19 -4.28

SRBCF vs MTNB, TCRT, QLGN: Equity-to-Asset Comparison

For the Biotechnology subindustry, Sirona Biochem's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Equity-to-Asset falls into.


Sirona Biochem Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sirona Biochem's Equity to Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Equity to Asset (A: Oct. 2023 )=Total Stockholders Equity/Total Assets
=-1.8090149468756/0.74343453988835
=-2.43

Sirona Biochem's Equity to Asset Ratio for the quarter that ended in Jul. 2024 is calculated as

Equity to Asset (Q: Jul. 2024 )=Total Stockholders Equity/Total Assets
=-2.5074870606971/0.5857439646748
=-4.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -4.28 mean?
Sirona Biochem (SRBCF) has a Equity-to-Asset of -4.28 as of Jul. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sirona Biochem and its competitors.
Is Sirona Biochem's Equity-to-Asset too high?
Sirona Biochem's current Equity-to-Asset is -4.28.
How does Sirona Biochem's Equity-to-Asset compare to MTNB and TCRT?
Sirona Biochem's Equity-to-Asset of -4.28 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sirona Biochem and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sirona Biochem's current Equity-to-Asset is -4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirona Biochem stock overvalued right now?
Sirona Biochem (SRBCF) has a current Equity-to-Asset of -4.28. The current Equity-to-Asset is -4.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sirona Biochem (SRBCF), the current Equity-to-Asset is -4.28 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirona Biochem Business Description

Address C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.